Virginia Tech Researchers Unlock New Cancer Treatments Through Biomaterial Design

Redefining cancer treatment strategies, researchers at Virginia Tech’s Fralin Biomedical Research Institute at VTC are focusing on modifying the physical characteristics of microscopic biomaterials to interact seamlessly with the body’s tissues. This innovative approach could pave the way for safer, more effective cancer therapies.

Physical Characteristics Key to Immune Cell Activation

Modifying the physical characteristics of biomaterials is proving to be a powerful tool in controlling immune cell behavior. This approach allows us to precisely target and activate innate immune cells, such as macrophages and natural killer cells, which play a critical role in the fight against cancer.

DaeYong Lee, Department of Biomedical Engineering and Mechanics, Virginia Tech College of Engineering

Historically, studies involving biomaterials showed promise but often failed in clinical trials, especially for specific tumor types. DaeYong Lee’s team is now prioritizing the refinement of physical attributes in biomaterials to improve their interaction with immune cells, shifting focus away from purely chemical property optimization.

Recent Breakthrough: Engineered Polypeptides

This research builds on a study published in Nature Biomedical Engineering in 2024, where Lee and his colleagues engineered positively charged proteins to activate immune pathways. These synthetic polypeptides promoted the release of mitochondrial DNA, which primed T cells to fight cancer. In mouse models of advanced breast cancer, these engineered polypeptides elicited potent antitumor immune responses, presenting a novel treatment option.

EunHye Kim Pioneers New Field

EunHye Kim, the study’s first author and a postdoctoral associate in the Lee lab, expressed excitement about this emerging field. “The design and optimization of biomaterials’ physical properties is an underexplored area with significant potential. It’s thrilling to be at the cutting edge of this rapidly advancing field, working towards discoveries that may someday help cancer patients,” Kim said.

Challenges and Future Directions

Despite these groundbreaking findings, challenges remain. Translating laboratory innovations into clinical applications requires addressing scalability, manufacturing, and safety across diverse patient populations. Interdisciplinary collaboration—spanning materials science, immunology, and clinical research—will be pivotal in overcoming these obstacles and establishing the groundwork for next-generation cancer treatments.

Dr. Lee Leads Cancer Research at Virginia Tech

Virginia Tech’s recruitment of Dr. Lee from MD Anderson Cancer Center in Houston underscores his importance in cancer research. His work, emphasized by the institute’s cancer research centers in Roanoke and Washington, D.C., reflects a transformative approach to cancer therapeutics made possible by a gift from the Red Gates Foundation.

Unlocking Potential for Cancer Patients

Lee’s lab focuses on transforming cancer therapy for patients with limited treatment options. By concentrating on the physical engineering of biomaterials, this research aims to open new avenues for cancer treatment and improve patient outcomes.

Potential Impact

These developments represent a step forward in personalized medicine, tailoring treatments to specific biological markers and tumor characteristics. As this field advances, it holds the promise of more effective, safer cancer therapies, revolutionizing the way we approach this global health challenge.